Romania's A&D Pharma makes appointments
This article was originally published in Scrip
A&D Pharma, one of Romania's largest pharmaceutical companies, has appointed Robert Musneci and Michael Schilling non-executive directors. Mr Musneci has worked for GlaxoSmithKline's local division for 15 years. Mr Schilling was managing partner of the local office of Linklaters, a law firm advising on commercial law in various sectors of the economy in 2000-07. The company cut the number of its board members from 13 to six, and appointed Walid Abboud, one the company's founding shareholders, its chairman.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.